Investigation Report on China's Liraglutide Market 2021-2025
No. of Pages: 50
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, developed by Novo Nordisk A/S. Its product VICTOZA firstly launched in the EU in July 2009 and
|
04-Jun-2021
|
2600
|
Investigation Report on China's Pertuzumab Market 2021-2025
No. of Pages: 50
Pertuzumab is the first monoclonal antibody called "HER dimerization inhibitor". It mainly used to treat HER2-positive breast cancer. It was developed by Genentech, a subsidiary
|
04-Jun-2021
|
2600
|
Investigation Report on China's Sitagliptin Market 2021-2025
No. of Pages: 50
Sitagliptin is the world's first listed oral dipeptidyl peptidase-4 (DPP-4) inhibitor, developed by Merck Sharp & Dohme Ltd (JANUVIA). It was approved by the U.S.
|
04-Jun-2021
|
2600
|
Investigation Report on China's Oxaliplatin Market 2021-2025
No. of Pages: 50
Oxaliplatin (OXA) is the third-generation platinum anti-tumor drug after cisplatin and carboplatin. Oxaliplatin was jointly developed by Sanofi and Debiopharm for the first-line treatment of
|
04-Jun-2021
|
2600
|
Investigation Report on China's Pantoprazole Market 2021-2025
No. of Pages: 50
Pantoprazole is the third proton pump inhibitor marketed globally. Compared with omeprazole, it has higher selectivity and bioavailability. Pantoprazole is more stable than omeprazole and
|
04-Jun-2021
|
2600
|
Investigation Report on China's Docetaxel Market 2021-2025
No. of Pages: 50
Docetaxel, sold under the brand name Taxotere, is a paclitaxel anti-tumor drug used for the treatment of locally advanced or metastatic non-small cell lung cancer.
|
04-Jun-2021
|
2600
|
Investigation Report on China's Tocilizumab Market 2021-2025
No. of Pages: 50
Description
The trade name of Tocilizumab is ACTEMRA, which was developed by Roche Pharma (Schweiz) AG. In 2013, its product was firstly approved in China and
|
28-May-2021
|
2600
|
Investigation Report on China's Golimumab Market 2021-2025
No. of Pages: 50
Description
Golimumab is an immunosuppressive medication that can effectively regulate inflammation and bone metabolism. The trade name of Golimumab is SIMPONI, which was developed by Janssen
|
28-May-2021
|
2600
|
Investigation Report on China's Abiraterone Market 2021-2025
No. of Pages: 50
Description
Abiraterone is a CYP17 inhibitor, which is mainly clinically used to treat prostate cancer patients. Its product ZYTIGA was developed by Janssen-Cilag International NV(a subsidiary
|
28-May-2021
|
2600
|
Investigation Report on China's Dasatinib Market 2021-2025
No. of Pages: 50
Description
Dasatinib, developed by Bristol-Myers Squibb, is an anti-tumor drug. It was first approved by the FDA in 2006 for the treatment of adult patients with
|
28-May-2021
|
2600
|
Investigation Report on China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) 2021-2025
No. of Pages: 50
Description
Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) is an effective drug for the prevention and treatment of neutropenia or deficiency caused by tumor radiotherapy
|
28-May-2021
|
2600
|
Investigation Report on China's Paclitaxel Market 2021-2025
No. of Pages: 50
Description
Paclitaxel is a chemotherapeutic tumor drug used to treat metastatic breast cancer after failure of combination chemotherapy or relapse within 6 months after adjuvant chemotherapy.
|
28-May-2021
|
2600
|
Investigation Report on China's Voriconazole Market 2021-2025
No. of Pages: 50
Description
Voriconazole is used to treat progressive, potentially life-threatening fungal infections. Its product was developed by Pfizer. It was approved in China in 2004. By 2020,
|
28-May-2021
|
2600
|
Investigation Report on China's Butylphthalide Market 2021-2025
No. of Pages: 50
Description
Butylphthalide, developed by CSPC Enbipu Pharmaceutical Co. Ltd is used to treat mild to moderate acute ischemic stroke. Its soft capsule was approved in China
|
28-May-2021
|
2600
|
Investigation Report on China's Esomeprazole Market 2021-2025
No. of Pages: 50
Description
Esomeprazole is a proton pump inhibitor (PPI), which can effectively inhibit gastric acid secretion. It is clinically used to treat gastric acid-related diseases such as
|
28-May-2021
|
2600
|
Investigation Report on China's Dolutegravir Market 2021-2025
No. of Pages: 50
Description
Dolutegravir was developed by GlaxoSmithKline for the treatment of HIV-infected adults and children over 12 years old. Its product TIVICAY was approved in China in
|
28-May-2021
|
2600
|
Investigation Report on China's Propofol Market 2021-2025
No. of Pages: 50
Description
Propofol is a short-acting intravenous anesthetic. Its uses include the induction and maintenance of general anesthesia, sedation for mechanically ventilated adults, and procedural sedation. It
|
28-May-2021
|
2600
|
Investigation Report on China's Tiotropium Bromide Market 2021-2025
No. of Pages: 50
Description
Tiotropium Bromide, developed by Boehringer Ingelheim International GmbH, is used to treat chronic obstructive pulmonary disease (COPD). Its product SPIRIVA was approved in China in
|
28-May-2021
|
2600
|
Investigation Report on Chinese Compound Amino Acid Market 2021-2025
No. of Pages: 50
Description
Compound Amino Acid is clinically used for patients with insufficient protein intake, malabsorption, and other amino acids that cannot meet the requirements of body metabolism.
|
28-May-2021
|
2600
|
Investigation Report on China's Piperacillin and Tazobactam Market 2021-2025
No. of Pages: 50
Description
Piperacillin and Tazobactam is a compound anti-infective drug composed of piperacillin (semi-synthetic penicillin antibiotic) and tazobactam (β-lactamase inhibitor). It is suitable for moderate and severe
|
28-May-2021
|
2600
|
